Search
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigational[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.
Tibolone
go.drugbank.com/drugs/DB09070ApprovedInvestigationalFood and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for tibolone had not been approved [L1722].
Amphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigational[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976.[L5194] During World War II, amphetamine was used to promote wakefulness in the soldiers.
Venlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigational[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997.
Products: Nra-venlafaxine XRTobramycin
go.drugbank.com/drugs/DB00684ApprovedInvestigational[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to
Bismuth subsalicylate
go.drugbank.com/drugs/DB01294ApprovedVet approved[A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.
Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigational[L32853] Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalIn June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.